French President Calls for Middle East Ceasefire, Trump Involved
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 09 2026
0mins
Should l Buy ABBV?
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.IRAN CEASEFIRE:President of France Emmanuel Macron said in a post on X: "I spoke today with Iranian President Massoud Pezeshkian, as well as with U.S. President Donald Trump. I told both of them that their decision to accept a ceasefire was the best possible one. I expressed my hope that the ceasefire will be fully respected by each of the belligerents, across all areas of confrontation, including in Lebanon. This is a necessary condition for the ceasefire to be credible and lasting. It must open the way to comprehensive negotiations capable of ensuring security for all in the Middle East. Any agreement will have to address the concerns raised by Iran's nuclear and ballistic missile programs, as well as its regional policy and its actions obstructing navigation through the Strait of Hormuz. This is how a strong and lasting peace can be built, with the support of all those who are able to contribute to it. France will play its full part, in close coordination with its partners in the Middle East. This is also what I discussed today in my exchanges with the leaders of Qatar, the United Arab Emirates, Lebanon, and Iraq."Meanwhile, the speaker of the Parliament of Iran, Mohammad Bagher Ghalibaf, said the country's ceasefire with the U.S. has been violated, according to Bloomberg. Ghalibaf said three clauses of the ceasefire had been violated so far.SANCTIONS:The U.S. is weighing lifting sanctions on Venezuela's central bank to facilitate the flow of cash into the South American nation's economy, Bloomberg's Andreina Itriago, Eric Martin, and Fabiola Zerpa, citing people familiar with the matter. A lift would allow proceeds from oil sales to move more freely through the country's financial system, the authors note.DISCOUNT DRUG PROGRAM:AbbVieis suing the Trump administration to get a clearer definition of who counts as an eligible patient in the government's discount drug program, Maya Goldman of Axios reports. AbbVie filed a lawsuit in the District Court for the District of Columbia, saying that definition is "overly inclusive, capturing individuals who may have had only a cursory encounter with the covered entity a long time ago," according to the website.GAIN VOUCHER:Nano Nuclear Energyannounced that it has been awarded a Gateway for Accelerated Innovations in Nuclear, or GAIN, Voucher, NE-26-38854, by U.S. Department of Energy, or DOE, relating to its Kronos MMR Energy System titled, "Uncertainty Quantification and Sensitivity Analysis Support for NANO Nuclear Reactor Design Using ORNL's Tools - SCALE/TSUNAMI". NANO Nuclear, in collaboration with the Oak Ridge National Laboratory, will apply the SCALE/TSUNAMI code suite to quantify the impact of nuclear data, modeling assumptions, and operational parameters on key reactor physics metrics, including reactivity, power distribution, and temperature coefficients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 208.990
Low
223.00
Averages
252.00
High
289.00
Current: 208.990
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of High-Yield Stock Investment Opportunities
- AbbVie's Appeal: AbbVie boasts a forward dividend yield of 3.3%, slightly above the S&P 500's 1.1%, and its status as a 'Dividend King' with 53 consecutive years of increases attracts both value and income investors, with solid growth expected ahead.
- Enbridge's Stability: Enbridge offers a robust 5.4% dividend yield and has increased its dividend for 31 consecutive years, operating over 18,000 miles of crude oil and 19,000 miles of natural gas pipelines, ensuring stability and visible growth opportunities in the energy sector.
- Realty Income's Growth Potential: Realty Income provides a 5% dividend yield and has also raised its dividend for 31 years, with a high occupancy rate of 98.9% and a diversified tenant base, positioning it well for growth, particularly in the European market.
- Market Environment Challenges: While the S&P 500 has rebounded after volatility, many growth stocks remain unstable, and rising bond yields necessitate a focus on the Federal Reserve's policy direction to capitalize on high-yield stock investment opportunities.
See More
Analysis of High-Yield Stock Investment Opportunities
- AbbVie's Dividend King Status: AbbVie boasts a forward dividend yield of 3.3%, slightly above the S&P 500's 1.1%, and its impressive 53-year streak of dividend increases positions it as a Dividend King, appealing to both value and income investors alike.
- Enbridge's Stability and Growth Potential: With a dividend yield of 5.4% and a 31-year history of increases, Enbridge operates over 18,000 miles of crude oil and 19,000 miles of natural gas pipelines, providing stable cash flow and visible growth opportunities, with around $50 billion identified for the next decade.
- Realty Income's Monthly Dividend Advantage: Realty Income offers a 5% dividend yield and has also increased its dividend for 31 consecutive years, with its unique monthly payment structure providing investors with more frequent cash flow, supported by a high occupancy rate of 98.9% that demonstrates resilience during economic downturns.
- Market Expansion and Competitive Edge: Realty Income's promising opportunities in Europe, with a total addressable market of $8.5 trillion and limited competition, are expected to drive sustained growth, while its diversified tenant base enhances its risk resilience.
See More
Three Stocks to Hold for 20 Years
- AbbVie's Adaptability: AbbVie (ABBV) generated over $1 billion in sales from 12 drugs last year, and despite facing patent expirations and competitive pressures, the company successfully launched successors Rinvoq and Skyrizi, surpassing Humira's peak sales, demonstrating its strong market adaptability and future growth potential.
- Amazon's Ecosystem: Amazon (AMZN), the world's largest consumer discretionary company, dominates not only in e-commerce but also continuously expands in cloud computing and artificial intelligence, creating a sticky ecosystem that is difficult for competitors to disrupt, which is expected to continue attracting a large user base and drive long-term growth.
- Enbridge's Stability: Enbridge (ENB) operates the world's longest network of oil and liquid pipelines and is the largest natural gas utility in North America, with strong demand expected to persist over the next 20 years, particularly as natural gas and liquids usage rises, while its dividend growth provides stable returns for investors.
- Dividend Kings Potential: Both AbbVie and Enbridge have over 30 years of dividend growth records, with AbbVie already a Dividend King, and Enbridge expected to join this elite group in 19 years, showcasing their strong capabilities in shareholder returns and the attractiveness of long-term investments.
See More
Investment Opportunities in Psychedelic Therapy
- Massive Market Potential: With 100 million people globally suffering from treatment-resistant depression, representing one-third of all depression cases, psychedelic therapy presents significant growth opportunities, especially where traditional treatments fail.
- FDA Trial Progress: Compass Pathways' COMP 360 recently demonstrated a well-tolerated safety profile in Phase 3 trials, leading to a stock surge of over 23%, indicating a shift towards mainstream acceptance of psychedelics and the potential birth of a new healthcare category.
- Shift in Treatment Models: Unlike traditional daily medications, psychedelic therapy is an interventional approach requiring only 1-6 sessions for lasting effects, which could reshape investor perceptions of mental health treatments and attract more capital into the sector.
- Competitive Advantages in the Industry: As clinical applications of psychedelics increase, early market entrants like Compass Pathways will gain significant competitive advantages, prompting investors to monitor these companies' clinical advancements and market strategies.
See More
Investment Opportunities in Psychedelic Therapy
- FDA-Backed Shift: The transition of psychedelics from a counterculture fringe movement to an FDA-backed clinical model signifies a major transformation in mental health treatment, likely attracting investor interest in this emerging market.
- Huge Market Potential: Compass Pathways' COMP 360 demonstrated a well-tolerated safety profile in Phase 3 trials, with stock surging over 23%, indicating significant market potential for treating resistant depression affecting approximately 100 million patients globally.
- Innovative Treatment Model: Psychedelic therapy employs an interventional approach, differing from traditional medications, where patients typically require only 1 to 6 sessions, potentially offering investors new business models and revenue streams, especially in the $10,000 to $20,000 treatment services.
- Industry Competitive Landscape: While Big Pharma has not fully engaged yet, companies like AbbVie have begun acquiring smaller psychedelic firms, indicating growing interest in this emerging field, which could reshape the market dynamics of mental health treatment in the future.
See More
AbbVie's Stock Pullback Represents a Long-Term Buying Opportunity
- Reason for Stock Pullback: AbbVie's stock, which reached a record high of $238.71 on October 1, 2025, has pulled back about 13%, primarily due to overly optimistic market expectations for its new immunology drugs, Skyrizi and Rinvoq, leading investors to take profits amid increasing macroeconomic pressures.
- Market Performance Analysis: Over the past four years, AbbVie's stock has doubled, with a market cap of $369 billion and a current price of $209.03, indicating that despite short-term volatility, the company's fundamentals remain strong, complemented by a 4.02% dividend yield that attracts income-seeking investors.
- Future Growth Expectations: Analysts project AbbVie's EPS to increase more than fivefold from 2025 to 2028, driven by surging sales of new drugs, and while much of this growth is already priced in, the stock is still considered reasonably valued at 24 times this year's earnings.
- Investment Value Assessment: Despite the pressure from rising interest rates, AbbVie is viewed as a safe investment choice, particularly in a turbulent market, as its stable dividends and robust earnings growth prospects make it an ideal option for long-term investors.
See More
Analysis of High-Yield Stock Investment Opportunities
- AbbVie's Appeal: AbbVie boasts a forward dividend yield of 3.3%, slightly above the S&P 500's 1.1%, and its status as a 'Dividend King' with 53 consecutive years of increases attracts both value and income investors, with solid growth expected ahead.
- Enbridge's Stability: Enbridge offers a robust 5.4% dividend yield and has increased its dividend for 31 consecutive years, operating over 18,000 miles of crude oil and 19,000 miles of natural gas pipelines, ensuring stability and visible growth opportunities in the energy sector.
- Realty Income's Growth Potential: Realty Income provides a 5% dividend yield and has also raised its dividend for 31 years, with a high occupancy rate of 98.9% and a diversified tenant base, positioning it well for growth, particularly in the European market.
- Market Environment Challenges: While the S&P 500 has rebounded after volatility, many growth stocks remain unstable, and rising bond yields necessitate a focus on the Federal Reserve's policy direction to capitalize on high-yield stock investment opportunities.
See More
Analysis of High-Yield Stock Investment Opportunities
- AbbVie's Dividend King Status: AbbVie boasts a forward dividend yield of 3.3%, slightly above the S&P 500's 1.1%, and its impressive 53-year streak of dividend increases positions it as a Dividend King, appealing to both value and income investors alike.
- Enbridge's Stability and Growth Potential: With a dividend yield of 5.4% and a 31-year history of increases, Enbridge operates over 18,000 miles of crude oil and 19,000 miles of natural gas pipelines, providing stable cash flow and visible growth opportunities, with around $50 billion identified for the next decade.
- Realty Income's Monthly Dividend Advantage: Realty Income offers a 5% dividend yield and has also increased its dividend for 31 consecutive years, with its unique monthly payment structure providing investors with more frequent cash flow, supported by a high occupancy rate of 98.9% that demonstrates resilience during economic downturns.
- Market Expansion and Competitive Edge: Realty Income's promising opportunities in Europe, with a total addressable market of $8.5 trillion and limited competition, are expected to drive sustained growth, while its diversified tenant base enhances its risk resilience.
See More
Three Stocks to Hold for 20 Years
- AbbVie's Adaptability: AbbVie (ABBV) generated over $1 billion in sales from 12 drugs last year, and despite facing patent expirations and competitive pressures, the company successfully launched successors Rinvoq and Skyrizi, surpassing Humira's peak sales, demonstrating its strong market adaptability and future growth potential.
- Amazon's Ecosystem: Amazon (AMZN), the world's largest consumer discretionary company, dominates not only in e-commerce but also continuously expands in cloud computing and artificial intelligence, creating a sticky ecosystem that is difficult for competitors to disrupt, which is expected to continue attracting a large user base and drive long-term growth.
- Enbridge's Stability: Enbridge (ENB) operates the world's longest network of oil and liquid pipelines and is the largest natural gas utility in North America, with strong demand expected to persist over the next 20 years, particularly as natural gas and liquids usage rises, while its dividend growth provides stable returns for investors.
- Dividend Kings Potential: Both AbbVie and Enbridge have over 30 years of dividend growth records, with AbbVie already a Dividend King, and Enbridge expected to join this elite group in 19 years, showcasing their strong capabilities in shareholder returns and the attractiveness of long-term investments.
See More
Investment Opportunities in Psychedelic Therapy
- Massive Market Potential: With 100 million people globally suffering from treatment-resistant depression, representing one-third of all depression cases, psychedelic therapy presents significant growth opportunities, especially where traditional treatments fail.
- FDA Trial Progress: Compass Pathways' COMP 360 recently demonstrated a well-tolerated safety profile in Phase 3 trials, leading to a stock surge of over 23%, indicating a shift towards mainstream acceptance of psychedelics and the potential birth of a new healthcare category.
- Shift in Treatment Models: Unlike traditional daily medications, psychedelic therapy is an interventional approach requiring only 1-6 sessions for lasting effects, which could reshape investor perceptions of mental health treatments and attract more capital into the sector.
- Competitive Advantages in the Industry: As clinical applications of psychedelics increase, early market entrants like Compass Pathways will gain significant competitive advantages, prompting investors to monitor these companies' clinical advancements and market strategies.
See More
Investment Opportunities in Psychedelic Therapy
- FDA-Backed Shift: The transition of psychedelics from a counterculture fringe movement to an FDA-backed clinical model signifies a major transformation in mental health treatment, likely attracting investor interest in this emerging market.
- Huge Market Potential: Compass Pathways' COMP 360 demonstrated a well-tolerated safety profile in Phase 3 trials, with stock surging over 23%, indicating significant market potential for treating resistant depression affecting approximately 100 million patients globally.
- Innovative Treatment Model: Psychedelic therapy employs an interventional approach, differing from traditional medications, where patients typically require only 1 to 6 sessions, potentially offering investors new business models and revenue streams, especially in the $10,000 to $20,000 treatment services.
- Industry Competitive Landscape: While Big Pharma has not fully engaged yet, companies like AbbVie have begun acquiring smaller psychedelic firms, indicating growing interest in this emerging field, which could reshape the market dynamics of mental health treatment in the future.
See More
AbbVie's Stock Pullback Represents a Long-Term Buying Opportunity
- Reason for Stock Pullback: AbbVie's stock, which reached a record high of $238.71 on October 1, 2025, has pulled back about 13%, primarily due to overly optimistic market expectations for its new immunology drugs, Skyrizi and Rinvoq, leading investors to take profits amid increasing macroeconomic pressures.
- Market Performance Analysis: Over the past four years, AbbVie's stock has doubled, with a market cap of $369 billion and a current price of $209.03, indicating that despite short-term volatility, the company's fundamentals remain strong, complemented by a 4.02% dividend yield that attracts income-seeking investors.
- Future Growth Expectations: Analysts project AbbVie's EPS to increase more than fivefold from 2025 to 2028, driven by surging sales of new drugs, and while much of this growth is already priced in, the stock is still considered reasonably valued at 24 times this year's earnings.
- Investment Value Assessment: Despite the pressure from rising interest rates, AbbVie is viewed as a safe investment choice, particularly in a turbulent market, as its stable dividends and robust earnings growth prospects make it an ideal option for long-term investors.
See More
